Belimumab: First targeted biological treatment for systemic lupus erythematosus
Open Access
- 1 December 2011
- journal article
- molecules of-the-millennium
- Published by SAGE Publications in Journal of Pharmacology and Pharmacotherapeutics
- Vol. 2 (4), 317-319
- https://doi.org/10.4103/0976-500x.85930
Abstract
J Pharmacol Pharmacother, Official publication of InPharm Association, IndiaKeywords
This publication has 19 references indexed in Scilit:
- Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trialThe Lancet, 2011
- An update on belimumab for the treatment of lupusBiologics: Targets and Therapy, 2011
- New and emerging treatment approaches to lupusBiologics: Targets and Therapy, 2010
- The role of B lymphocyte stimulator (BLyS) in systemic lupus erythematosusJCI Insight, 2009
- Understanding the Epidemiology and Progression of Systemic Lupus ErythematosusSeminars in Arthritis and Rheumatism, 2009
- The BLyS Family: Toward a Molecular Understanding of B Cell HomeostasisCell Biochemistry and Biophysics, 2008
- Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosusArthritis & Rheumatism, 2008
- Chronic Administration of Belimumab, a BLyS Antagonist, Decreases Tissue and Peripheral Blood B-Lymphocyte Populations in Cynomolgus Monkeys: Pharmacokinetic, Pharmacodynamic, and Toxicologic EffectsToxicological Sciences, 2006
- B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: Longitudinal observationsArthritis & Rheumatism, 2003
- BAFF, a Novel Ligand of the Tumor Necrosis Factor Family, Stimulates B Cell GrowthThe Journal of Experimental Medicine, 1999